18 Jul Specific Biologics
Brent Stead, Ph.D., CEO
Oct. 6 | 9:30am | FLW Ballroom F
Toronto, Ontario, Canada
(Private)
Specific Biologics Inc. is a venture-backed biotechnology company developing Dualase®, an industry-leading genome editing platform for precise, efficient, and programmable in vivo genome editing. Our initial therapeutic focus is on the precise collapse of pathogenic repeat expansions, leaving non-pathogenic numbers of repeats, using intrathecally delivered single AAV9 in a neurodegenerative disease. Its unique two-site mechanism enables the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects which has been demonstrated in preclinical cell and animal models at diverse targets and indications with clear paths to clinic in CNS, liver and lung diseases.
